FDA halts Amgen study after teen patient death
Posted 2/26/13
WASHINGTON (AP) — Federal health regulators have halted Amgen's studies of its thyroid drug Sensipar after the death of a 14-year-old patient in a company trial.
The Food and Drug Administration said Tuesday it is still gathering information …
This item is available in full to subscribers
Subscribe to continue reading. Already a subscriber? Sign in
Local reporters bringing you local news. Stay in the know about all things Sumter.
You can cancel anytime.